A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients "MARINER"

Recruiting

Phase 3 Results N/A

Summary of Purpose

The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 15 November 2017.

2 Jun 2014 31 Mar 2014 25 May 2018 25 May 2018 1 Nov 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:

    JNJ.CT@sylogent.com

  • This study is not yet recruiting patients. Please check back for future recruiting sites, or email

    JNJ.CT@sylogent.com